Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy
WIREs Nanomedicine and Nanobiotechnology · 2026-03 · 18 (2)
DOI: 10.1002/wnan.70052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 09.03.2026. Verfasst von Yanying He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana, USA. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Immunotherapy, Imidazoles, Neoplasms. Die Arbeit nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Over the past decade, immunotherapy has emerged as the fourth pillar of cancer therapy, following surgery, chemotherapy, and radiotherapy. However, tumors often evade immune responses by altering the tumor microenvironment (TME), which recruits immunosuppressive cells such as myeloid‐derived suppressor cells (MDSCs), tumor‐associated macrophages, and regulatory T cells. Among these, MDSCs are considered key contributors to immunotherapy failure and have become major targets in new therapeutic strategies. Growing evidence indicates that controlling MDSCs is critical to the success of cancer immunotherapy, and several drug classes have shown feasibility. In this review, we introduce the significance of MDSCs as a target in cancer immunotherapy and highlight different therapeutic approaches to counteract their immunosuppressive functions. We discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod (R848) as a representative drug candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, Indiana, USA.
- Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA.
- Purdue University Institute for Cancer Research, West Lafayette, Indiana, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
He, Y., & Yeo, Y. (2026). Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy. WIREs Nanomedicine and Nanobiotechnology, 18(2). https://doi.org/10.1002/wnan.70052
Vancouver
He Y, Yeo Y. Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy. WIREs Nanomedicine and Nanobiotechnology. 2026;18(2). doi:10.1002/wnan.70052
BibTeX
@article{He2026,
author = {He, Yanying and Yeo, Yoon},
title = {Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2026},
volume = {18},
number = {2},
doi = {10.1002/wnan.70052}
}
EUVIMED